References

1. Gao P, Morozowich W. Case studies: rational development of self-emulsifying formulations for improving the oral bioavailability of poorly soluble, lipophilic drugs. Chapter 12.

2. Bagwe RP, Kanicky JR, Palla BJ, Patanjali PK, Shah DO. Improved drug delivery using microemulsions: rationale, recent progress, and new horizons. Critical Rev Therap Drug Carrier Syst 2001; 18(1):77-140.

3. Wasan KM. Formulations and physiological and biopharmaceutical issues in the development of oral lipid-based drug delivery systems. Drug Devel Ind Pharm 2001; 27(4):267-276.

4. Charman WN. Lipids, lipophilic drugs and oral drug delivery—some emerging concepts. J Pharm Sci 2000; 89:967-978.

5. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and "self-microemulsifying" drug delivery systems. Eur J Pharm Sci 2002; 11(suppl):S93-S98.

6. Wignot TM, Stewart RP, Schray KJ, Das S, Sipos T. In vitro studies of the effects of HAART drugs and excipients on activity of digestive enzymes. Pharm Res 2004; 21(3):420-427.

7. Sherman DS, Fish DN. Management of protease inhibitor associated diarrhea. Clin Infec Dis 2000; 30:908-914.

8. Poelma FGJ, Breas R, Tukker JJ, Crommelin DJA. Intestinal absorption of drugs. The influence of mixed micelles on the disappearance kinetics of drugs from the small intestine of the rat. J Pharm Pharmacol 1991; 43(5):317-324.

9. Poelma FGJ, Breas R, Tukker JJ, Josef J. Intestinal absorption of drugs. III. The influence of taurocholate on the disappearance kinetics of hydrophilic and lipophilic drugs from the small intestine of the rat. Pharm Res 1990; 7(4):392-397.

10. Chiu YY, Higaki K, Neudeck BL, Barnett JL, Welage LS, Amidon GL. Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cells. Pharm Res 2003; 20(5):749-756.

11. Higuchi T. Physical chemical analysis of the percutaneous absorption process. J Soc Cosmetic Chem 1960; 11:85-97.

12. Megrab NA, Williams AC, Barry BW. Oestradiol permeation through human skin silastic membrane: effects of propylene glycol and supersaturation. J Control Rel 1995; 36:277-294.

13. Ma X, Taw J, Chiang C. Control of drug crystallization in transdermal matrix systems. Int J Pharm 1996; 142:115-119.

14. Schwarb FP, Imanidis G, Smith EW, Haigh JM, Surber C. Effect of concentration and degree of saturation of topical fluocinonide formulations on in vitro membrane transport and in vivo availability on human skin. Pharm Res 1997; 16:909-915.

15. Raghavan SL, Trividic A, Davis AF, Hadgraft J. Crystallization of hydrocortisone acetate: influence of polymers. Int J Pharm 2001; 212:213-221.

16. Raghavan RL, Kiepfer B, Davis AF, Kazarian SG, Hadgraft J. Membrane transport of hydrocortisone acetate from supersaturated solutions: the role of polymers. Int J Pharm 2001; 221:95-105.

17. Pellet MA, Davis AF, Hadgraft J. Effect of supersaturation on membrane transport: 2. Piroxicam. Int J Pharm 1994; 111:1-6.

18. Pellet MA, Castellano S, Hadgraft J, Davis AF. The penetration of supersaturated solutions of piroxicam across silicone membranes and human skin in vitro. J Control Rel 1997; 46:205-214.

19. Pellet MA, Roberts MS, Hadgraft J. Supersaturated solutions evaluated with an intro stratum corneum tape stripping technique. Int J Pharm 1997; 151:91-98.

20. Raghavan RL, Trividic A, Davis AF, Hadgraft J. Effects of cellulose polymers on supersaturation and in vitro membrane transport of hydrocortisone acetate. Int J Pharm 2000; 193:231-237.

21. Iervolino M, Raghavan RL, Hadgraft J. Membrane penetration enhancement of ibuprofen using supersaturation. Int J Pharm 2000; 198:229-238.

22. Iervolino M, Cappello B, Raghavan RL, Hadgraft J. Penetration enhancement of ibuprofen from supersaturated solutions through human skin. Int J Pharm 2001; 212:131-141.

23. Simonelli AP, Mehta SC, Higuchi WI. Inhibition of sulfathiazole crystal growth by polyvinylpyrrolidone. J Pharm Sci 1970; 59:633-638.

24. Sekikawa H, Fujiwara J, Naganuma T, Nakano M, Arita T. Dissolution behaviors and gastrointestinal absorption of phenytoin in phenytoin-polyvinylpyrrolidone coprecipi-tate. Chem Pharm Bull 1978; 26;3033-3039.

25. Suzuki H, Sunada H. Comparison of nicotiamide, ethylurea and polyethylene glycol as carriers for nifedipine solid dispersion systems. Chem Pharm Bull 1997; 45(10):1688-1693.

26. Suzuki H, Sunada H. Some factors influencing the dissolution of solid dispersions with nicotiamide and hydroxypropylmethycellulose as combined carriers. Chem Pharm Bull 1998; 46(6):1015-1020.

27. Yamada T, Saito N, Imai T, Otagiri M. Effect of grinding with hydroxypropyl cellulose on dissolution and particle size of a poorly water-soluble drug. Chem Pharm Bull 1999; 47(9):1311-1313.

28. Kohri N, Yamayoshi Y, Xin H, et al. Improving the oral bio-availability of albendazole in rabbits by the solid dispersion technique. J Pharm Pharmacol 1999; 51:159-164.

29. Hasegawa A, Nakagawa H, Sugimoto I. Application of solid dispersions of nifedip-ine with enteric coating agent to prepare a sustained-release dosage form. Chem Pharm Bull 1985; 33(4):1615-1619.

30. O'Driscoll KM, Corrigan OI. Chlorothiazide-polyvinylpyrrolidone (PVP) interactions: influence on membrane permeation (everted rat intestine) and dissolution. Drug Dev Ind Pharm 1982; 8(4):547-564.

31. Usui F, Maeda K, Kusai A, Nishimura K, Yamamoto K. Inhibitory effects of water soluble polymers on precipitation of RS-8359. Int J Pharm 1997; 154:59-66.

32. Hasegawa A, Taguchi M, Suzuki R, Miyata T, Nakagawa H, Sugimoto I. Supersaturation mechanism of drugs from solid dispersions with enteric coating agents. Chem Pharm Bull 1988; 36(12):4941-4950.

33. Gao P, Guyton ME, Huang T, Bauer JM, Stefanski KJ, Lu Q. Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations. Drug Dev Ind Pharm 2004; 30(2):221-229.

34. Gao P, Rush RD, Pfund WP, et al. Development of a supersaturatable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J Pharm Sci 2003; 92(12):2395-2407.

35. Tang L, Khan SU, Muhammad NA. Evaluation and selection of bio-relevant dissolution media for a poorly water soluble new chemical entity. Pharm Dev Tech 2002; 6(4):531-540.

36. Humberstone AJ, Charman WN. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Dev Rev 1997; 25:103-128.

37. Sek L, Porter CJH, Kaukonen AM, Charman WN. Evaluation of the in vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipophilic products. J Phar Pharmaco 2002; 54:29-41.

38. Lee J, Lee SC, Acharya G, Chang C, Park K. Hydrotropic solubilization of paclitax-el: analysis of chemical structures for hydro tropic property. Pharm Res 2003; 20(7):1022-1030.

39. Straudinger RM. Biopharmaceutics of paclitaxel (Taxol®): formulation, activity, and pharmacokinetics. In: Suffness M, ed., Taxol Science and Applications. Chap. 9. New York: CRC Press Inc., 1995.

40. Mathew AE, Mejillano MR, Nath JP, Himes RH, Stella VJ. Synthesis and evaluation of some water-insoluble prodrugs and derivatives of Taxol with antitumor activity. J Med Chem 1992; 35:145-149.

41. Trissel LA, ed. Handbook on Injectable Drugs. 8th ed. Bethesda, MD: Am Soc Hosp Pharm Inc., 1994:808.

42. Nuijen B, Bouma M, Schellens JHM, Beijnen JH. Progress in the development of alternative pharmaceutical formulations of taxanes. Inv New Drugs 2001; 19:143-153.

43. Zuylen LV, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Inv New Drugs 2001; 19:125-141.

44. Lassus M, Scott D, Leyland JB. Allergic reactions associated with cremophor containing antineoplastics. Proc Am Soc Clin Oncol 1985; 4:268.

45. Malingre MM, Beijnen JH, Schellens JHM. Oral delivery of taxanes. Inv New Drugs 2001; 19:155-162.

46. Bardeleijer HA, Tellingen OV, Schellens JHM, Beijnen JH. The oral route of the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery. Inv New Drugs 2000; 18:231-241.

47. Terwogt JMM, Malingre MM, Beijnen JH, et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 1999; 5:3379-3384.

48. Malingre MM, Beijnen JH, Rosing H, et al. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. Cancer Chemother Pharmacol 2001; 47:347-354.

49. Woo JS, Lee CH, Shim CK, Hwang SJ. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res 2003; 20:24-30.

50. Montaseri H, Jamali F, Micetich RG, Daneshtalab M. Improving oral bioavailability of Taxol. Pharm Res 1995; 12:S-429.

51. Lennernaes H, Fagerholm U, Raab Y, Gerdin B, Haellgren R. Regional rectal perfusion: a new in vivo approach to study rectal drug absorption in man. Pharm Res 1995; 12(3):426-432.

52. Takamatsu Narushi, Welage Lynda S, Idkaidek Nasir M, et al. Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG400 determined by jejunal perfusion. Pharm Res 1997; 14(9):1127-1132.

53. Ho NFH, Day JS, Barsuhn CL, Burton PS, Raub TJ. Biophysical model approaches to mechanistic transepithelial studies of peptides. J Cont Rel 1990; 11(1-3):3-24.

54. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharma-ceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12(3):413-420.

55. Amidon GE, Higuchi WI, Ho NF. Theoretical and experimental studies of transport of micelle-solubilized solutes. J Pharm Sci 1982; 71(1):77-84.

56. Haque A, Morris ER. Thermogelation of methylcellulose. Part I. Molecular structures and processes. Carbohydrate Polymers 1993; 22:161-173.

57. Haque A, Richardson RK, Morris ER, Gidley MJ, Caswell DC. Thermogelation of methylcellulose. Part II. Effect of hydroxypropyl substituents. Carbohydrate Polymers 1993; 22:175-186.

58. Ziller KH, Rupprecht H. Control of crystal growth in drug suspensions. Drug Dev Ind Pharm 1988; 14:2341-2370.

Was this article helpful?

0 0

Post a comment